InteKrin garners $23M in VC

Sofinnova Ventures has led a round of $23 million for InteKrin Therapeutics, which is pursuing therapies for diabetes and obesity. InteKrin was set up in 2005 by Amgen exec Denny Lanfear and Harvard Med professor Christos Mantzoros, M.D. The money is earmarked for the clinical development of a type 2 diabetes drug.

- see the release on the round
- read the report from the San Francisco Business Times

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.